# Comparing the Effects of Sublingual Estradiol Treatment Versus Oral Estradiol With Cyproterone Acetate (CPA) Treatment on The Coagulation System in Transgender Women: A Prospective, Controlled Cohort Study

> **NCT07145281** · NA · COMPLETED · sponsor: **Tel-Aviv Sourasky Medical Center** · enrollment: 30 (actual)

## Conditions studied

- Gender Dysphoria, Adult
- Blood Coagulation
- Coagulation Factors
- Transgender Persons, M01.777.500
- Hemostasis
- Transgender Women

## Interventions

- **DRUG:** Estradiol (E2)
- **DRUG:** Cyproterone Acetate (Androcur, BAY94-8367)

## Key facts

- **NCT ID:** NCT07145281
- **Lead sponsor:** Tel-Aviv Sourasky Medical Center
- **Sponsor class:** OTHER_GOV
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-11-10
- **Primary completion:** 2024-11-10
- **Final completion:** 2024-11-10
- **Target enrollment:** 30 (ACTUAL)
- **Last updated:** 2025-08-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07145281

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07145281, "Comparing the Effects of Sublingual Estradiol Treatment Versus Oral Estradiol With Cyproterone Acetate (CPA) Treatment on The Coagulation System in Transgender Women: A Prospective, Controlled Cohort Study". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT07145281. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*